TB006 (TrueBinding): An Inflammation-First Monoclonal Antibody Strategy for Alzheimer’s Disease
TB006 is an investigational monoclonal antibody from TrueBinding that targets galectin-3, aiming to reduce amyloid aggregation and neuroinflammation in Alzheimer’s disease. Early Phase 2a data show trends toward slowed clinical decline and some cognitive improvement, and it is currently accessible mainly through the FDA Expanded Access Program. This is the first allopathic treatment ever to […]